Burkina Faso

Burkina Faso

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
12.18 (10.07 - 14.09) 2019 Modelled IHME
12.01 (10.11 - 13.84) 2018 Modelled IHME
11.98 (10.10 - 13.95) 2017 Modelled IHME
12.85 (11.01 - 14.82) 2016 Modelled IHME
14.01 (11.94 - 16.23) 2015 Modelled IHME
14.56 (12.42 - 16.68) 2014 Modelled IHME
15.02 (12.84 - 17.20) 2013 Modelled IHME
15.4 (13.03 - 17.49) 2012 Modelled IHME
15.71 (13.34 - 17.96) 2011 Modelled IHME
15.97 (13.42 - 18.40) 2010 Modelled IHME
16.23 (13.53 - 18.70) 2009 Modelled IHME
16.47 (13.68 - 18.96) 2008 Modelled IHME
16.69 (13.74 - 19.21) 2007 Modelled IHME
16.84 (13.82 - 19.49) 2006 Modelled IHME
16.9 (13.72 - 19.70) 2005 Modelled IHME
16.84 (13.69 - 19.59) 2004 Modelled IHME
16.71 (13.51 - 19.56) 2003 Modelled IHME
16.55 (13.34 - 19.51) 2002 Modelled IHME
16.42 (13.15 - 19.51) 2001 Modelled IHME
16.37 (13.14 - 19.63) 2000 Modelled IHME
16.48 (13.18 - 19.59) 1999 Modelled IHME
16.75 (13.35 - 19.81) 1998 Modelled IHME
17.07 (13.66 - 20.15) 1997 Modelled IHME
17.34 (13.88 - 20.53) 1996 Modelled IHME
17.45 (13.93 - 20.69) 1995 Modelled IHME
17.42 (13.88 - 20.56) 1994 Modelled IHME
17.32 (13.84 - 20.40) 1993 Modelled IHME
17.14 (13.74 - 20.11) 1992 Modelled IHME
16.89 (13.53 - 19.80) 1991 Modelled IHME
16.55 (13.26 - 19.36) 1990 Modelled IHME
10.05 (8.20 - 12.28) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
1.81 (1.22 - 2.34) 2019 Modelled IHME
1.83 (1.27 - 2.38) 2018 Modelled IHME
1.86 (1.32 - 2.47) 2017 Modelled IHME
1.9 (1.40 - 2.41) 2016 Modelled IHME
1.94 (1.46 - 2.52) 2015 Modelled IHME
1.99 (1.52 - 2.51) 2014 Modelled IHME
2.03 (1.56 - 2.52) 2013 Modelled IHME
2.08 (1.61 - 2.58) 2012 Modelled IHME
2.14 (1.67 - 2.66) 2011 Modelled IHME
2.24 (1.74 - 2.80) 2010 Modelled IHME
3.54 (2.72 - 4.37) 2009 Modelled IHME
6.47 (4.89 - 8.01) 2008 Modelled IHME
9.93 (7.44 - 12.34) 2007 Modelled IHME
12.81 (9.42 - 16.03) 2006 Modelled IHME
14.01 (10.14 - 17.73) 2005 Modelled IHME
13.97 (10.11 - 17.63) 2004 Modelled IHME
13.86 (10.04 - 17.52) 2003 Modelled IHME
13.72 (10.04 - 17.44) 2002 Modelled IHME
13.61 (9.99 - 17.33) 2001 Modelled IHME
13.57 (9.97 - 17.50) 2000 Modelled IHME
13.67 (9.97 - 17.49) 1999 Modelled IHME
13.9 (10.06 - 17.75) 1998 Modelled IHME
14.17 (10.14 - 18.15) 1997 Modelled IHME
14.41 (10.20 - 18.39) 1996 Modelled IHME
14.5 (10.09 - 18.79) 1995 Modelled IHME
14.47 (10.12 - 18.63) 1994 Modelled IHME
14.38 (10.05 - 18.36) 1993 Modelled IHME
14.23 (10.06 - 18.28) 1992 Modelled IHME
14 (9.91 - 17.91) 1991 Modelled IHME
13.71 (9.77 - 17.68) 1990 Modelled IHME
4.29 (3.03 - 5.77) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
36 (29 - 44) 2019 Modelled IHME
36 (29 - 44) 2018 Modelled IHME
36 (28 - 44) 2017 Modelled IHME
37 (29 - 45) 2016 Modelled IHME
37 (30 - 46) 2015 Modelled IHME
38 (30 - 46) 2014 Modelled IHME
38 (30 - 46) 2013 Modelled IHME
38 (30 - 46) 2012 Modelled IHME
38 (30 - 46) 2011 Modelled IHME
38 (30 - 46) 2010 Modelled IHME
38 (30 - 46) 2009 Modelled IHME
38 (30 - 46) 2008 Modelled IHME
38 (30 - 46) 2007 Modelled IHME
38 (30 - 46) 2006 Modelled IHME
38 (31 - 46) 2005 Modelled IHME
38 (31 - 46) 2004 Modelled IHME
38 (31 - 46) 2003 Modelled IHME
38 (30 - 46) 2002 Modelled IHME
38 (31 - 46) 2001 Modelled IHME
38 (30 - 46) 2000 Modelled IHME
38 (31 - 46) 1999 Modelled IHME
38 (31 - 46) 1998 Modelled IHME
38 (31 - 46) 1997 Modelled IHME
39 (31 - 46) 1996 Modelled IHME
39 (31 - 47) 1995 Modelled IHME
39 (31 - 47) 1994 Modelled IHME
39 (31 - 47) 1993 Modelled IHME
39 (31 - 47) 1992 Modelled IHME
39 (30 - 47) 1991 Modelled IHME
39 (30 - 47) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
91 2018 Survey/reported WHO/UNICEF
91 2017 Survey/reported WHO/UNICEF
91 2016 Survey/reported WHO/UNICEF
91 2015 Survey/reported WHO/UNICEF
91 2014 Survey/reported WHO/UNICEF
88 2013 Survey/reported WHO/UNICEF
90 2012 Survey/reported WHO/UNICEF
91 2011 Survey/reported WHO/UNICEF
91 2010 Survey/reported WHO/UNICEF
92 2009 Survey/reported WHO/UNICEF
93 2008 Survey/reported WHO/UNICEF
89 2007 Survey/reported WHO/UNICEF
76 2006 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
0 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.03 (2.41 - 3.83) 2019 Modelled IHME
3.04 (2.42 - 3.83) 2018 Modelled IHME
3.06 (2.43 - 3.83) 2017 Modelled IHME
3.13 (2.52 - 3.88) 2016 Modelled IHME
3.18 (2.57 - 3.93) 2015 Modelled IHME
3.19 (2.58 - 3.95) 2014 Modelled IHME
3.19 (2.58 - 3.96) 2013 Modelled IHME
3.2 (2.58 - 3.98) 2012 Modelled IHME
3.2 (2.58 - 3.97) 2011 Modelled IHME
3.2 (2.57 - 3.98) 2010 Modelled IHME
3.2 (2.58 - 3.98) 2009 Modelled IHME
3.21 (2.59 - 3.97) 2008 Modelled IHME
3.22 (2.61 - 3.99) 2007 Modelled IHME
3.22 (2.61 - 4) 2006 Modelled IHME
3.23 (2.61 - 3.99) 2005 Modelled IHME
3.24 (2.63 - 3.99) 2004 Modelled IHME
3.25 (2.64 - 3.99) 2003 Modelled IHME
3.26 (2.64 - 4.03) 2002 Modelled IHME
3.28 (2.65 - 4.06) 2001 Modelled IHME
3.3 (2.67 - 4.10) 2000 Modelled IHME
3.33 (2.69 - 4.15) 1999 Modelled IHME
3.39 (2.75 - 4.25) 1998 Modelled IHME
3.46 (2.81 - 4.37) 1997 Modelled IHME
3.52 (2.85 - 4.46) 1996 Modelled IHME
3.55 (2.86 - 4.50) 1995 Modelled IHME
3.56 (2.88 - 4.48) 1994 Modelled IHME
3.57 (2.87 - 4.48) 1993 Modelled IHME
3.58 (2.88 - 4.48) 1992 Modelled IHME
3.58 (2.87 - 4.49) 1991 Modelled IHME
3.59 (2.86 - 4.51) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
11.6 (4.30 - 29.70) 2014 Modelled Gower et al, 2014

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
21 (15 - 28) 2019 Modelled IHME
21 (15 - 27) 2018 Modelled IHME
21 (15 - 27) 2017 Modelled IHME
20 (14 - 27) 2016 Modelled IHME
20 (14 - 27) 2015 Modelled IHME
21 (14 - 27) 2014 Modelled IHME
21 (15 - 27) 2013 Modelled IHME
21 (15 - 28) 2012 Modelled IHME
21 (15 - 28) 2011 Modelled IHME
21 (15 - 28) 2010 Modelled IHME
21 (15 - 28) 2009 Modelled IHME
22 (15 - 28) 2008 Modelled IHME
22 (16 - 28) 2007 Modelled IHME
22 (15 - 28) 2006 Modelled IHME
21 (15 - 28) 2005 Modelled IHME
22 (15 - 28) 2004 Modelled IHME
22 (15 - 28) 2003 Modelled IHME
22 (16 - 29) 2002 Modelled IHME
22 (16 - 29) 2001 Modelled IHME
22 (16 - 29) 2000 Modelled IHME
23 (16 - 29) 1999 Modelled IHME
23 (16 - 30) 1998 Modelled IHME
23 (16 - 30) 1997 Modelled IHME
23 (16 - 30) 1996 Modelled IHME
23 (16 - 30) 1995 Modelled IHME
23 (16 - 30) 1994 Modelled IHME
23 (16 - 30) 1993 Modelled IHME
23 (16 - 30) 1992 Modelled IHME
23 (16 - 30) 1991 Modelled IHME
23 (16 - 30) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (0 - 0) 2016 Survey/reported Harm Reduction International, 2016

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
12.18 (%)
2019
(10.07 - 14.09(%))
IHME
HCV (RNA/cAg+)
3.03 (%)
2019
(2.41 - 3.83(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
1,402
2019
(825 - 2,036)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
294
2019
(174 - 427)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
1.81 (%)
2019, latest modelled
(1.22 - 2.34(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines